Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome.
Annabel NiessenM S M van MourikA H W BrunsR A P RaijmakersM C H de GrootT van der BruggenPublished in: Antimicrobial resistance and infection control (2020)
The introduction of a protocol promoting restrictive use of EAT resulted in reduction of carbapenem and vancomycin use and appears to be safe in AML or high-risk MDS patients with febrile neutropenia during chemotherapy or SCT.
Keyphrases